Hameln Rds Extends Its Portfolio in Pre-clinical Studies

Hameln Rds Now Able to Perfom Pre-clinical Studies for Transdermal Aystems

Hameln / Paris, 05. October 2010. hameln rds has once again extended its portfolio: At its research and development site in Modra, Slovakia, the company can now also perform pre-clinical studies for transdermal systems, using mini-pigs as animal models. In many cases, pre-clinical studies on transdermal systems are the prerequisite for clinical studies. Clinical studies, on the other hand, are stringently required to bring a pharmaceutical product into the market.

As pig skin is almost analogous to human skin, both histological and physiological, and mini-pigs are thus the animal model of choice when it comes to testing transdermal drug delivery systems.First experiences have already been made in a long-term chronic toxicology study, forming the basis for a clinical study phase II
which will be organised by hameln rds.

By integrating these studies into its portfolio hameln rds has once again rounded out the value chain it is offering to its customers.Comp